Ustekinumab clinical trials
Ustekinumab is named as an intervention in 23 current clinical trials in our Canada, USA, Belgium, China, Germany, Poland, UK, France, Spain, Italy, Czechia, Japan, South Korea, Australia, Netherlands, Austria, Denmark, Brazil, Switzerland, Turkey, Israel, Sweden, Mexico, Taiwan, Portugal, Norway, India and Egypt registers. 13 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Janssen Research & Development, LLC (3). The most-studied condition is Crohn Disease. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Where Ustekinumab is approved
All regulators →Of the three regulators tracked here, the first to approve Ustekinumab was Canada, on 12 Dec 2008. It is approved in 3 of the 3 regulators tracked here.
- 10 FDA-approved biosimilars, 10 interchangeable: Imuldosa, Otulfi, Pyzchiva, Pyzchiva and others
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Ustekinumab
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Ustekinumab works
All drug targets →- Interleukin-12 inhibitor InhibitorTarget: Interleukin-12ChEMBL only
- Interleukin-23 inhibitor InhibitorTarget: Interleukin-23ChEMBL only
- Takayasu arteritisPhase 3
- Ankylosing spondylitisPhase 3
- DermatomyositisPhase 3
- Intestinal obstructionPhase 3
- Palmoplantar pustulosisPhase 3
- PolymyositisPhase 3
- PouchitisPhase 3
- Psoriasis-related juvenile idiopathic arthritisPhase 3
- Rheumatoid arthritisPhase 3
- Systemic lupus erythematosusPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201835, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6885, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Ustekinumab
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 5 technology appraisals of Ustekinumab. 5 are current, and 5 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Ustekinumab for treating moderately to severely active ulcerative colitis NICE TA633 | Optimised | 17 Jun 2020 | Current |
| Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people NICE TA455 | Optimised | 12 Jul 2017 | Current |
| Ustekinumab for moderately to severely active Crohn’s disease after previous treatment NICE TA456 | Recommended | 12 Jul 2017 | Current |
| Ustekinumab for treating active psoriatic arthritis NICE TA340 | Optimised | 4 Jun 2015 Updated 3 Mar 2017 | Current |
| Ustekinumab for treating moderate to severe plaque psoriasis NICE TA180 | Recommended | 23 Sep 2009 Updated 3 Mar 2017 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Ustekinumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 49 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EU
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Ustekinumab
- ATC code
- L04AC05
- ChEMBL
- CHEMBL1201835
- DrugBank
- DB05679
- CAS number
- 815610-63-0
- FDA UNII
- FU77B4U5Z0
- Wikidata
- Q420305
- Wikipedia
- Ustekinumab
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Ustekinumab
23 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Ustekinumab in the EU trials register (CTIS)
3 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Ustekinumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma
2026-526036-38-00 · Neoplasms
|
Phase 2 | Authorised | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Netherlands |
|
FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial
2024-514964-24-00 · CTIS ↗ · Digestive System Diseases
|
Phase 3 | Authorised | University Hospital Of Clermont-Ferrand | France |
|
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
2024-514848-88-00 · CTIS ↗ · Therapeutics
|
Phase 2 | Authorised | Assistance Publique Hopitaux De Paris | France |
Ustekinumab across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
49 single-substance products containing Ustekinumab on the HPRA medicines list.
- Fymskina 130 mg Concentrate for solution for infusionFormycon AG · EU/1/24/1862/003
- Fymskina 45 mg Solution for injectionFormycon AG · EU/1/24/1862/001
- Fymskina 90 mg Solution for injectionFormycon AG · EU/1/24/1862/002
- Imuldosa 130 mg Concentrate for solution for infusionAccord Healthcare S.L.U. · EU/1/24/1872/003
- Imuldosa 45 mg Solution for injectionAccord Healthcare S.L.U. · EU/1/24/1872/001
Supply shortages
No entry for Ustekinumab in the EMA, FDA or German BfArM shortage lists we track.
Recent approvals
- UsgenaEMA · 17 Nov 2025 · biosimilar · Stada Arzneimittel AG
Conditions studied with Ustekinumab
21 conditionsAll 21 conditions
| Condition (as registered) | Trials |
|---|---|
| Crohn Disease | 7 |
| Plaque Psoriasis | 3 |
| Psoriasis | 3 |
| Crohn's Disease | 3 |
| Colitis, Ulcerative | 2 |
| Stricture; Bowel | 2 |
| Crohn Disease (CD) | 2 |
| Ulcerative Colitis (UC) | 2 |
| Crohn's Disease (CD) | 1 |
| Arthritis, Psoriatic | 1 |
| Moderate to Severe Plaque Psoriasis | 1 |
| Intestinal Stricture | 1 |
| Inflamatory Bowel Disease | 1 |
| CD - Crohn's Disease | 1 |
| IBD - Inflammatory Bowel Disease | 1 |
| Ulcerative Colitis | 1 |
| Inflammatory Bowel Diseases | 1 |
| Type 1 Diabetes Mellitus | 1 |
| Rheumatoid Arthritis | 1 |
| Ankylosing Spondylitis | 1 |
| Psoriatic Arthritis | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 3 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Bristol-Myers Squibb | 1 |
| Janssen-Cilag International NV | 1 |
| AbbVie | 1 |
| UCB Biopharma SRL | 1 |
| Janssen Scientific Affairs, LLC | 1 |
| Takeda | 1 |
| Shanghai 10th People's Hospital | 1 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 1 |
| Celltrion HealthCare France | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| University Medical Center Groningen | 1 |
| Medical University of Lodz | 1 |
| Swiss Dermatology Network for Targeted Therapies | 1 |
+ 5 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Ustekinumab trials
How many clinical trials are testing Ustekinumab?
23 current trials in our Canada, USA, Belgium, China, Germany, Poland, UK, France, Spain, Italy, Czechia, Japan, South Korea, Australia, Netherlands, Austria, Denmark, Brazil, Switzerland, Turkey, Israel, Sweden, Mexico, Taiwan, Portugal, Norway, India and Egypt registers name Ustekinumab (also registered as CNTO 1275) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.
Are Ustekinumab trials recruiting patients?
Yes. 13 of the 23 trials are recruiting: 2 with sites in Canada, 2 with sites in USA, 2 with sites in Belgium, 5 with sites in China, 1 with sites in Germany, 2 with sites in Poland, 1 with sites in UK, 2 with sites in France, 1 with sites in Spain, 2 with sites in Italy, 1 with sites in Czechia, 1 with sites in Japan, 2 with sites in South Korea, 1 with sites in Australia, 1 with sites in Netherlands, 1 with sites in Denmark, 1 with sites in Brazil, 1 with sites in Switzerland, 1 with sites in Sweden, 1 with sites in Mexico and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Ustekinumab clinical trials?
Janssen Research & Development, LLC (3), Second Affiliated Hospital, Zhejiang University, School of Medicine (2), Bristol-Myers Squibb (1) and Janssen-Cilag International NV (1), among 20 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Ustekinumab licensed in Ireland?
Yes. The HPRA medicines list includes 49 single-substance products containing Ustekinumab, for example Fymskina 130 mg Concentrate for solution for infusion (Formycon AG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Ustekinumab shortage?
Not in the lists we track: Ustekinumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ustekinumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ustekinumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ustekinumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.